search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Open, randomized trial of the effect of aripiprazole versus risperidone on social cognition in schizophrenia.


- candidate number1793
- NTR NumberNTR405
- ISRCTNISRCTN61441186
- Date ISRCTN created27-jan-2006
- date ISRCTN requested18-nov-2005
- Date Registered NTR27-okt-2005
- Secondary IDsN/A 
- Public TitleOpen, randomized trial of the effect of aripiprazole versus risperidone on social cognition in schizophrenia.
- Scientific TitleOpen, randomized trial of the effect of aripiprazole versus risperidone on social cognition in schizophrenia.
- ACRONYMN/A
- hypothesisWe hypothesize that, because of its unique action as a partial dopamine agonist in brain circuits underlying social cognition, treatment with aripiprazole will lead to a significant improvement in social cognitive processing compared to risperidone.
- Healt Condition(s) or Problem(s) studiedSchizophrenia
- Inclusion criteria1. DSM-IV based diagnosis of schizophrenia;
2. Age 18 - 50;
3. Active anticonception;
4. IQ > 80;
5. Negative pregnancy test.
- Exclusion criteria1. Pregnancy;
2. Lactation;
3. Severe head trauma;
4. Substance abuse.
- mec approval receivedno
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-dec-2005
- planned closingdate1-dec-2007
- Target number of participants80
- Interventions80 schizophrenia patients are randomly assigned to either risperidone (4 mg) or aripiprazole (15 mg).
- Primary outcomeThe effect of treatment with risperidone or aripiprazole on social cognitive processes in patients with schizophrenia is the primary result of this study. These processes are assessed using computerised cognitive tasks. The objective of the study is to determine which of the two antipsychotics is the most effective against social cognitive deficits.
- Secondary outcomeN/A
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIES Thomas Rietkerk
- CONTACT for SCIENTIFIC QUERIES Thomas Rietkerk
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
Bristol-Myers, Squibb
- PublicationsN/A
- Brief summaryImpairments in social functioning are a hallmark characteristic of schizophrenia. Deficits in social functioning are present throughout the course of the disorder. Indeed, they are even present before the onset of psychosis (Davidson et al. 1999) and frequently persist despite antipsychotic treatment (Addington & Addington 2000).

The study of social cognition in schizophrenia examines the processes underlying social dysfunction (Corrigan & Penn, 2001; Pinkham et al. 2003). Social cognition has been defined as ?the mental operations underlying social interactions, which include the human ability to perceive the intentions and dispositions of others?. A crucial finding is that performance on social cognition tasks predicts social functioning (Penn et al. 2000; Pinkham et al. 2003).

Brain circuits underlying social cognition concern the ventral striatum, the amygdala, the medial prefrontal and orbitofrontal cortex, anterior cingulate, and insula (Phan et al. 2002; Pinkham et al. 2003). The importance of dopamine pathways in neural processing in these circuits is well established (Grace 2000).

Until now, antipsychotics have not been able to reverse the social deficits associated with schizophrenia, which might be due to their general antagonist activity at dopamine D2 receptors. We hypothesize that, because of its unique action as a partial dopamine agonist in brain circuits underlying social cognition, treatment with aripiprazole will lead to a significant improvement in social cognitive processing compared to risperidone. Computerised behavioral tasks are used to measure social cognition and questionnaires and inventories are used to map social functioning in patients with schizophrenia.
- Main changes (audit trail)
- RECORD27-okt-2005 - 13-jan-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl